Blog

Exploring a New Avenue in Vaccine Development: Targeting Conserved Epitopes with Broadly Neutralizing Antibodies

Antibody Discovery /

SARS-CoV-2’s ability to evolve quickly creates ongoing challenges for vaccine development. The spike protein, critical for the virus’s cell infection, undergoes rapid mutations, making antibodies less effective against new strains. Traditional vaccines, with their lengthy development and testing timelines, struggle to predict these evolutionary changes accurately, leading to a constant struggle to keep pace with […]

Exploring a New Avenue in Vaccine Development: Targeting Conserved Epitopes with Broadly Neutralizing Antibodies Read More »

Published in Scientific Reports: Understanding Antibody-Secreting Cells: A Closer Look at Cellular Dynamics with Optofluidic Precision

Antibody Discovery, Infectious Disease, Vaccines /

The behavior of early-minted antibody-secreting cells (ASC) or plasmablasts post-infection or vaccination plays a pivotal role in the immune response. Traditionally, long-lived plasma cells (LLPC) from the bone marrow are regarded as non-dividing, while blood ASCs are thought to be proliferative. Traditional technologies that average bulk data or measure surface phenotype alone miss critical functional

Published in Scientific Reports: Understanding Antibody-Secreting Cells: A Closer Look at Cellular Dynamics with Optofluidic Precision Read More »

Published in Frontiers in Molecular Medicine: Revolutionizing CAR-T Cell Manufacturing for Enhanced Therapeutic Responses with Bruker’s Single-Cell Instruments

CAR T Therapy /

In the rapidly evolving landscape of cancer treatment, chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapeutic approach, garnering FDA approval in 2017. However, the journey from initial success to widespread efficacy has been marked by challenges, prompting researchers to continuously reevaluate and refine CAR-T manufacturing processes. A recent review published

Published in Frontiers in Molecular Medicine: Revolutionizing CAR-T Cell Manufacturing for Enhanced Therapeutic Responses with Bruker’s Single-Cell Instruments Read More »

Published in Antibody Therapeutics: Alpaca Single B Cell Interrogation and Heavy-Chain-Only Antibody Discovery on the Beacon® Platform

Antibody Discovery /

Researchers have used Bruker Cellular Analysis’ Optofluidic technology to establish the fastest high-resolution workflow for the discovery and engineering of VHH antibodies yet. Scientists developed a novel application leveraging Bruker’s optofluidic Beacon® platform to detect IgG2/3 antibodies from activated memory B cells derived from alpaca peripheral blood samples. B cells secreting PSMA-specific antibodies were recovered

Published in Antibody Therapeutics: Alpaca Single B Cell Interrogation and Heavy-Chain-Only Antibody Discovery on the Beacon® Platform Read More »

Bruker Cellular Analysis Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows

Announcement /

Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16th annual PEACe Conference Bruker Cellular Analysis is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September

Bruker Cellular Analysis Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows Read More »

Revolutionizing Antibody Discovery: How the Beacon Optofluidics System is Saving Time and Resources

Cancer Immunology, Infectious Disease, Inflammation & Neurology, Oncology /

Biologics have immense commercial potential. However, developing successful candidates can feel like looking for a needle in a haystack. Research, development, manufacturing, and clinical testing are limited by substantial time and cost considerations. But what if you could identify a higher quantity of quality hits in a fraction of the time and with a fraction

Revolutionizing Antibody Discovery: How the Beacon Optofluidics System is Saving Time and Resources Read More »

Published in Head & Neck: Cytokine Profiling Reveals How Novel Kinase Inhibitor Slows Tumor Cell Growth by Altering Tumor Microenvironment

Cancer Immunology /

Every year, head and neck cancers (HNC) claim thousands of lives, with over 54,000 cases diagnosed annually in the United States alone, resulting in approximately 11,000 fatalities.1 HNCs are particularly difficult to treat—about one in three patients will not survive five years after diagnosis, despite a range of treatment options including surgery, radiation, chemotherapy, and

Published in Head & Neck: Cytokine Profiling Reveals How Novel Kinase Inhibitor Slows Tumor Cell Growth by Altering Tumor Microenvironment Read More »

Published in Science Translational Medicine: Single-Cell Secretome Reveals Functional Profiles of Immune Cells in Hard-To-Treat Cancers

Cancer Immunology /

Cancer has long been one of the most challenging diseases to treat as traditional treatments, like chemotherapy and radiation, can be harsh on the body and are not always successful. However, recent advancements in the field of immunotherapy have improved anti-cancer treatments; one of the more promising immunotherapy approaches being Immune Checkpoint Blockade (ICB) therapy.

Published in Science Translational Medicine: Single-Cell Secretome Reveals Functional Profiles of Immune Cells in Hard-To-Treat Cancers Read More »

Revolutionizing Immunotherapy Research and Development With the New Opto® T Cell Profiling Workflow

Cancer Immunology /

Polyfunctional T cells, which produce multiple cytokines, are considered to be the most potent anti-tumor effector T cells. To find polyfunctional T cells in a heterogeneous sample, researchers must be able to characterize functional cytokine secretion and cytotoxicity at the single-cell level. However, most existing methods evaluate samples in bulk and are destructive endpoint assays,

Revolutionizing Immunotherapy Research and Development With the New Opto® T Cell Profiling Workflow Read More »

Bruker Cellular Analysis at PEGS Boston: Interrogating the Phenome at the Cutting Edge of Biotherapeutics

Events /

Bruker Cellular Analysis is looking forward to attending the upcoming PEGS Boston Summit from May 15-19. PEGS is the world’s largest gathering of protein engineering and biotherapeutics experts, and we are excited for the opportunity to meet with industry leaders and demonstrate how our groundbreaking platform is empowering researchers to leverage the full potential of

Bruker Cellular Analysis at PEGS Boston: Interrogating the Phenome at the Cutting Edge of Biotherapeutics Read More »